Barry I Freedman1, Jasmin Divers1, Gregory B Russell1, Nicholette D Palmer1, Lynne E Wagenknecht1, S Carrie Smith1, Jianzhao Xu1, J Jeffrey Carr1, Donald W Bowden1, Thomas C Register1. 1. Department of Internal Medicine, Section on Nephrology (B.I.F.), Center for Genomics and Personalized Medicine Research (B.I.F., J.D., G.B.R., N.D.P., J.X., D.W.B.), Center for Diabetes Research (B.I.F. J.D., G.B.R., N.D.P., L.E.W., J.X.), Center for Public Health Genomics (B.I.F. J.D., G.B.R., N.D.P., D.W.B.), Division of Public Health Sciences-Department of Biostatistical Sciences (J.D., G.B.R., L.E.W.), Department of Biochemistry (N.D.P., S.C.S., J.X.), and Department of Pathology (T.C.R.), Wake Forest School of Medicine, Winston-Salem, NC 27157; and Department of Radiology (J.J.C.), Vanderbilt University School of Medicine, Nashville, TN 37240.
Abstract
CONTEXT: Vitamin D binding protein (DBP) is an important determinant of bioavailable vitamin D (BAVD) and may provide clues to racial variation in osteoporosis and atherosclerosis. OBJECTIVE: The objective was to assess relationships between DBP, BAVD, 25-hydroxyvitamin D (25OHD), and 1,25 di-hydroxyvitamin D (1,25OH2D) with kidney, bone, adipose, and atherosclerosis phenotypes in African Americans with type 2 diabetes. DESIGN: Cross-sectional (N = 545) and longitudinal (N = 288; mean 5.1 ± 0.9-year follow-up) relationships between vitamin D concentrations with renal phenotypes, vertebral bone mineral density, aorto-iliac, coronary artery, and carotid artery calcified plaque (CP), and adipose tissue volumes were studied. SETTING: African American-Diabetes Heart Study. PATIENTS: Participants were 56.7% female with mean ± standard deviation (sd) age 55.6 ± 9.6 years, diabetes duration 10.3 ± 8.2 years, and eGFR 90.9 ± 22.1 ml/min/1.73 m(2). INTERVENTIONS: None. MAIN OUTCOMES AND MEASURES: Associations tested between vitamin D and the previously mentioned phenotypes adjusting for age, sex, African ancestry proportion, diabetes duration, statins, smoking, changes in estimated glomerular filtration rate, body mass index, hemoglobin A1c, and blood pressure. RESULTS: 1,25OH2D was inversely associated with change in coronary artery CP (parameter estimate [β] -0.005, standard error [SE] 0.002; P = .037), with a trend for change in carotid artery CP (β -0.007, SE 0.004; P = .074). Further adjustment for renin-aldosterone-system blockade revealed inverse association between 1,25OH2D and change in albuminuria (β -0.004, SE 0.002; P = .037). DBP, BAVD, and 25OHD did not associate significantly with changes in albuminuria, CP, or bone mineral density. BAVD was inversely associated with visceral, subcutaneous, intermuscular, and pericardial adipose volumes. CONCLUSIONS: In contrast to BAVD and 25OHD, only 1,25OH2D levels were significantly and inversely associated with changes in subclinical atherosclerosis and albuminuria in African Americans, suggesting potential beneficial effects.
CONTEXT: Vitamin D binding protein (DBP) is an important determinant of bioavailable vitamin D (BAVD) and may provide clues to racial variation in osteoporosis and atherosclerosis. OBJECTIVE: The objective was to assess relationships between DBP, BAVD, 25-hydroxyvitamin D (25OHD), and 1,25 di-hydroxyvitamin D (1,25OH2D) with kidney, bone, adipose, and atherosclerosis phenotypes in African Americans with type 2 diabetes. DESIGN: Cross-sectional (N = 545) and longitudinal (N = 288; mean 5.1 ± 0.9-year follow-up) relationships between vitamin D concentrations with renal phenotypes, vertebral bone mineral density, aorto-iliac, coronary artery, and carotid artery calcified plaque (CP), and adipose tissue volumes were studied. SETTING: African American-Diabetes Heart Study. PATIENTS: Participants were 56.7% female with mean ± standard deviation (sd) age 55.6 ± 9.6 years, diabetes duration 10.3 ± 8.2 years, and eGFR 90.9 ± 22.1 ml/min/1.73 m(2). INTERVENTIONS: None. MAIN OUTCOMES AND MEASURES: Associations tested between vitamin D and the previously mentioned phenotypes adjusting for age, sex, African ancestry proportion, diabetes duration, statins, smoking, changes in estimated glomerular filtration rate, body mass index, hemoglobin A1c, and blood pressure. RESULTS: 1,25OH2D was inversely associated with change in coronary artery CP (parameter estimate [β] -0.005, standard error [SE] 0.002; P = .037), with a trend for change in carotid artery CP (β -0.007, SE 0.004; P = .074). Further adjustment for renin-aldosterone-system blockade revealed inverse association between 1,25OH2D and change in albuminuria (β -0.004, SE 0.002; P = .037). DBP, BAVD, and 25OHD did not associate significantly with changes in albuminuria, CP, or bone mineral density. BAVD was inversely associated with visceral, subcutaneous, intermuscular, and pericardial adipose volumes. CONCLUSIONS: In contrast to BAVD and 25OHD, only 1,25OH2D levels were significantly and inversely associated with changes in subclinical atherosclerosis and albuminuria in African Americans, suggesting potential beneficial effects.
Authors: Lynne E Wagenknecht; Jasmin Divers; Alain G Bertoni; Carl D Langefeld; J Jeffrey Carr; Donald W Bowden; Steven C Elbein; Steven Shea; Cora E Lewis; Barry I Freedman Journal: Ann Epidemiol Date: 2011-01 Impact factor: 3.797
Authors: N Vilarrasa; J Maravall; A Estepa; R Sánchez; C Masdevall; M A Navarro; P Alía; J Soler; J M Gómez Journal: J Endocrinol Invest Date: 2007-09 Impact factor: 4.256
Authors: John F Aloia; Manish Patel; Rhett Dimaano; Melissa Li-Ng; Sonia A Talwar; Mageda Mikhail; Simcha Pollack; James K Yeh Journal: Am J Clin Nutr Date: 2008-06 Impact factor: 7.045
Authors: Barry I Freedman; Lynne E Wagenknecht; Kristen G Hairston; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Ethel J Gordon; Jianzhao Xu; Carl D Langefeld; Jasmin Divers Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Kendra A Young; Corinne D Engelman; Carl D Langefeld; Kristen G Hairston; Steven M Haffner; Michael Bryer-Ash; Jill M Norris Journal: J Clin Endocrinol Metab Date: 2009-06-23 Impact factor: 5.958
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Christina L Wassel; James S Pankow; Carmen A Peralta; Shweta Choudhry; Michael F Seldin; Donna K Arnett Journal: Circ Cardiovasc Genet Date: 2009-09-19
Authors: J R Shaffer; C M Kammerer; D Reich; G McDonald; N Patterson; B Goodpaster; D C Bauer; J Li; A B Newman; J A Cauley; T B Harris; F Tylavsky; R E Ferrell; J M Zmuda Journal: Osteoporos Int Date: 2007-01-18 Impact factor: 5.071
Authors: L Lenchik; T C Register; G B Russell; J Xu; S C Smith; D W Bowden; J Divers; B I Freedman Journal: Osteoporos Int Date: 2018-05-31 Impact factor: 4.507
Authors: Lynne E Wagenknecht; Jasmin Divers; Thomas C Register; Gregory B Russell; Donald W Bowden; Jianzhao Xu; Carl D Langefeld; Leon Lenchik; Keith A Hruska; J Jeffrey Carr; Barry I Freedman Journal: J Clin Endocrinol Metab Date: 2016-08-23 Impact factor: 5.958
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Jianzhao Xu; S Carrie Smith; Donald W Bowden; Thomas C Register; J Jeffrey Carr; Leon Lenchik; Barry I Freedman Journal: PLoS One Date: 2018-01-24 Impact factor: 3.240
Authors: Eu Jeong Ku; Kyung-Cho Cho; Cheong Lim; Jeong Won Kang; Jae Won Oh; Yu Ri Choi; Jong-Moon Park; Na-Young Han; Jong Jin Oh; Tae Jung Oh; Hak Chul Jang; Hookeun Lee; Kwang Pyo Kim; Sung Hee Choi Journal: BMJ Open Diabetes Res Care Date: 2020-04
Authors: Armin Zittermann; Jana B Ernst; Tobias Becker; Jens Dreier; Cornelius Knabbe; Jan F Gummert; Joachim Kuhn Journal: Int J Anal Chem Date: 2016-04-05 Impact factor: 1.885